HHS Confirms Providers’ Right to 340B Discount Pricing for Contract Pharmacies

January 5, 2021 Alerts and Newsletters

As a holiday gift to providers, the U.S. Department of Health and Human Services (HHS) General Counsel recently issued a strongly worded Advisory Opinion indicating that federal law requires drug manufacturers to deliver covered outpatient drugs purchased by providers at 340B discounted rates to contract pharmacies, so that contract pharmacies can dispense such drugs to patients on behalf of providers. See HHS General Counsel Advisory Opinion, dated December 30, 2020. During 2020, several manufacturers refused to deliver 340B discounted drugs to contract pharmacies, though providers had ordered and paid for the drugs. HHS issued the Advisory Opinion in response to numerous requests from both providers and manufacturers regarding the propriety of the manufacturers’ refusal to provide the drugs to contract pharmacies.

In the Advisory Opinion, HHS concluded that the 340B statute could not be “less ambiguous” in requiring that manufacturers offer covered outpatient drugs at no more than the 340B ceiling price for purchase by providers, regardless of how the providers intend to dispense the drugs. HHS also noted that not allowing contract pharmacies to dispense covered outpatient drugs would undercut a main purpose of the 340B Program, which seeks to benefit providers that are remote, small, resource-limited, receiving federal assistance, or serving disadvantaged populations. As HHS put it, “[t]hese are the poster children of providers that one would expect to lack an in-house pharmacy,” meaning contract pharmacies are a necessary link in the 340B distribution chain. HHS noted that denying discounts due to contract pharmacy use would foreclose 95% of all 340B discounts, a nonsensical result.

The Advisory Opinion confirms HHS’s consistent affirmation of the use of contract pharmacies. HHS noted that if manufacturers are genuinely concerned about diversion and duplicate discounts for 340B drugs—the manufacturers’ stated reasons for refusing to provide discounted drugs to contract pharmacies—they can proceed through the available dispute resolution channels, which now include a formal alternative dispute resolution process implemented by the recent adoption of the final rule. See Verrill Client Alert, dated December 14, 2020.

On balance, the Advisory Opinion is a positive development for providers, though it is possible that manufacturers will not view the Advisory Opinion as legally binding, as it is neither law nor regulation. It is also possible that the incoming presidential administration will take a different view of manufacturer requirements vis à vis contract pharmacies, though a pro-manufacturer change in position seems highly unlikely. Still, for now, the Advisory Opinion strongly and unequivocally establishes HHS’s current view that manufacturers must provide 340B discounts for covered outpatient drugs dispensed through contract pharmacies.

Firm Highlights

Publication/Podcast

“If I've told you once, I've told you eight times…” HHS OIG Issues Another Audit Report on Hospitals’ Failure to Report Credits for Explanted Cardiac Devices and Lays the Groundwork Collection of Overpayments

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Publication/Podcast

Hospital Price Transparency Rule: Full Steam Ahead

Neither COVID-19 nor continued legal challenges appear likely to derail the Centers for Medicare & Medicaid Services ( CMS) Hospital Price Transparency Rule from going into effect on January 1, 2021. Hospitals therefore should...

Publication/Podcast

340B Providers Get Partial Relief from New Dispute Resolution Regulation

1. 340B ADR Process Established At long last, more than ten years after Congress directed it to do so, HHS has finalized an alternative dispute resolution (“ADR”) process for both providers and pharmaceutical manufacturers...

Publication/Podcast

The Regulatory Sprint is Over - What’s at the Finish Line Under the New Stark and AKS Final Rules?

The U.S. Department of Health and Human Services (HHS) completed its “Regulatory Sprint” by finalizing changes to regulations pertaining to two federal fraud and abuse laws. On December 2, 2020, the Centers for Medicare...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Matter

Common Rule

Guided multiple clients through the implementation of the revised HHS regulations (the "Common Rule"), including reviewing and revising policies and procedures, and assisting with institutional approaches to implementation.

Contact Verrill at (855) 307 0700